Literature DB >> 1098588

Purification and some properties of malarial pigment.

C A Homewood, G A Moore, D C Wwarhurst, E M Atkinson.   

Abstract

Malarial pigment from erythrocytes infected with Plasmodium berghei was purified by treatment with sodium dodecyl sulphate solution, followed by incubation with Pancreatin. The purified pigment retained the apparently crystalline form of pigment within the parasite, rotated polarised light and had the same solubility characterisation as crude malarial pigment. It contained about 1% iron, all of which could be accounted for in terms of haemin. The iron of the pigment molecule is oxidised by the parasite to the ferric state.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1098588     DOI: 10.1080/00034983.1975.11687012

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  7 in total

Review 1.  Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors.

Authors:  Ernst Hempelmann
Journal:  Parasitol Res       Date:  2006-11-17       Impact factor: 2.289

Review 2.  Biochemistry of Plasmodium (malarial parasites).

Authors:  I W Sherman
Journal:  Microbiol Rev       Date:  1979-12

Review 3.  Malarial hemozoin: from target to tool.

Authors:  Lorena M Coronado; Christopher T Nadovich; Carmenza Spadafora
Journal:  Biochim Biophys Acta       Date:  2014-02-17

Review 4.  Antimalarial drugs. An update.

Authors:  D C Warhurst
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

Review 5.  Hemozoin: oil versus water.

Authors:  John M Pisciotta; David Sullivan
Journal:  Parasitol Int       Date:  2007-10-13       Impact factor: 2.230

6.  Hemolysis of mouse erythrocytes by ferriprotoporphyrin IX and chloroquine. Chemotherapeutic implications.

Authors:  A C Chou; C D Fitch
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

7.  The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria.

Authors:  Lena Serghides
Journal:  PPAR Res       Date:  2011-06-09       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.